GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invivyd Inc (NAS:IVVD) » Definitions » Market Cap

Invivyd (Invivyd) Market Cap : $230.28 Mil (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Invivyd Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Invivyd's share price for the quarter that ended in Mar. 2024 was $4.44. Invivyd's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 119.22 Mil. Therefore, Invivyd's market cap for the quarter that ended in Mar. 2024 was $529.34 Mil.

Invivyd's quarterly market cap increased from Sep. 2023 ($186.74 Mil) to Dec. 2023 ($434.03 Mil) and increased from Dec. 2023 ($434.03 Mil) to Mar. 2024 ($529.34 Mil).

Invivyd's annual market cap declined from Dec. 2021 ($804.28 Mil) to Dec. 2022 ($163.57 Mil) but then increased from Dec. 2022 ($163.57 Mil) to Dec. 2023 ($434.03 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Invivyd's Enterprise Value for Today is $42.65 Mil.


Invivyd Market Cap Historical Data

The historical data trend for Invivyd's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invivyd Market Cap Chart

Invivyd Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Market Cap
- 804.28 163.57 434.03

Invivyd Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.18 115.05 186.74 434.03 529.34

Competitive Comparison of Invivyd's Market Cap

For the Biotechnology subindustry, Invivyd's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invivyd's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invivyd's Market Cap distribution charts can be found below:

* The bar in red indicates where Invivyd's Market Cap falls into.



Invivyd Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Invivyd's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$3.94*110.161
=$434.03

Invivyd's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$4.44*119.221
=$529.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invivyd  (NAS:IVVD) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Invivyd Market Cap Related Terms

Thank you for viewing the detailed overview of Invivyd's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Invivyd (Invivyd) Business Description

Traded in Other Exchanges
N/A
Address
1601 Trapelo Road, Suite 178, Waltham, MA, USA, 02451
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Executives
Adimab, Llc 10 percent owner, other: See Remarks 7 LUCENT DRIVE, LEBANON NH 03766
William E. Duke officer: Chief Financial Officer C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Sara Cotter director 1735 MARKET STREET, FLOOR 23, PHILADELPHIA PA 19103
Allen Robert D. Iii officer: Chief Scientific Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Stacy Price officer: Chief Tech. and Manuf. Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jeremy Gowler officer: COO & CCO 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Rebecca Dabora officer: Chief Tech and Manuf Officer 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Peter Schmidt officer: Chief Medical Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jill Andersen officer: Chief Legal Officer, Secretary 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Christine Lindenboom director 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Frederick W Driscoll officer: Interim CFO
David Hering director, officer: Chief Executive Officer 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Marc Elia director, other: See Remarks C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
M28 Capital Management Lp other: See Remarks 700 CANAL STREET, 2ND FLOOR, STAMFORD CT 06902
Clive Meanwell director, 10 percent owner THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054

Invivyd (Invivyd) Headlines

From GuruFocus